In vitro physiological and antibacterial characterization of ZnO nanoparticle composites in simulated porcine gastric and enteric fluids

Table 3 Antimicrobial activity of commercial ZnO, ZnO nano, ZnO/CAT and ZnO/CA against Staphylococcus aureus

Samples	Sample concentration (μg/mL)	Concentration of incorporated Zn²⁺ (μg/mL)^a	S. aureus inhibition (%)
Commercial ZnO	200	198	45.6 ± 1.3
	500	495	63.5 ± 1.4
	650	643,5	100 ± 0.00
ZnO nano	150	117	22.7 ± 1.1
	200	156	58.3 ± 1.0
	250	195	100 ± 0.0
ZnO/CAT	1000	102	4.6 ± 0.6
	1250	127.5	16.6 ± 0.9
	2000	204	100 ± 0.0
ZnO/CA	500	63	6.3 ± 0.2
	750	94.5	43.8 ± 0.2
	1000	126	100 ± 0.0

^aAverage concentration of incorporated Zn²⁺ as determined by atomic absorption spectrophotometry: commercial ZnO, 99%, ZnO nano, 78 mass%; ZnO/CAT, 10.2 mass%; ZnO/CA, 12.6 mass%

ISSN: 1746-6148